Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $803.17, giving the company a market capitalization of 85.41B. It carries a P/E multiple of 18.89 and pays a dividend yield of 44.9%.
During the trading session on 2026-02-13, Regeneron(REGN) shares reached a daily high of $806.18 and a low of $785.00. At a current price of $803.17, the stock is +2.3% higher than the low and still -0.4% under the high.
Trading volume for Regeneron(REGN) stock has reached 879.99K, versus its average volume of 869.76K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals (REGN) is launching a Phase 3 trial called ROXI...
Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron are running a proof-of-concept Phase...
Advertisement What Regeneron’s Recent Trading Says About Investor Focus Regeneron Pharmaceuticals (REGN) has seen mixed share performance recently, with a 3.3...
Analyst ratings
72%
of 29 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The study, titled “A Randomized, Double-blind, Placebo-c...
Regeneron Pharmaceuticals (REGN) announced 36 abstracts across its immunology and inflammation portfolio and pipeline will be presented at the 2026 American Aca...
Regeneron Pharmaceuticals has reported past full-year 2025 results showing modest revenue and net income growth, completed a US$1.51 billion share repurchase, a...
Guggenheim raised the firm’s price target on Regeneron (REGN) to $975 from $865 and keeps a Buy rating on the shares. The firm, which updated its model after ea...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.